US Equities Analysis

BAX — Baxter International

BAX Price Chart FCF Yield Dividend Yield Price / Earnings Price / Book EV / EBITDA EV / NOPAT Consensus EPS Broker Sentiment EBITDA Margin EBIT Margin ROIC & ROE Capital Turnover Capex & WC / Sales Net Debt / Equity Price and 100d MA Relative to Index Relative to MSCI


1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 10.49B.

1.2 Competition

The industry is moderately competitive with established players and meaningful barriers to entry. Beta of 0.64 suggests moderate market sensitivity. Competitive advantages stem from brand, scale, or regulatory moats.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 6.03%
Profit Margins -9.7%
Return on Equity -15.01%
Return on Assets 2.85%
Free Float 0.51B
Dividend Yield 0.91%
Short Int % Utilisation 12.96%

2.2 Growth

Metric Value
Revenue Growth 2.9%
Free Cash Flow 0.9B
EBITDA 9.5 (Ratio)
Enterprise Value 18.13B
EV/Revenue 1.6
EV/EBITDA 9.5

Revenue growth of 2.9% suggests mature or challenged top-line momentum.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) -20.17%
Risk / Std Dev (Ann.) 33.77%
Sharpe Ratio (rf=4.5%) -0.73
Beta 0.64

2.5 Valuation

Metric Value
P/E (Forward) 10.07
Price/Book 1.72
EV/Revenue 1.6
EV/EBITDA 9.5
Enterprise Value / NOPAT 11.95
FCF Yield (%) 8.68%
Price / Book 1.72
Enterprise Value / EBITDA 9.44

Forward P/E of 10x is within a reasonable range for the company’s peer group.

2.6 Return Outlook

The stock’s historical risk-return profile shows an annualised expected return of -20.2% with annualised volatility of 33.8%, yielding a Sharpe ratio of -0.73 (rf=4.5%). The risk-adjusted return is below the risk-free rate, suggesting compensation for risk may be inadequate. With a beta of 0.6, the stock is less volatile than the market, offering relative downside protection.


us-equitystockequitybaxhealth-carehealth-care-equipmentnasdaq